Judgment — Oral sole-added biotin and cognition in adults with mild cognitive impairment
research showsCurrent evidence does not establish that oral sole-biotin supplementation improves cognition in adults with MCI. Related human data exist but do not isolate the sole-biotin treatment effect; the present R/I/B schema cannot validly encode the no-direct-decisive-study state, so grade and score remain null.
ads claimMechanistic or dietary claims for biotin/B-vitamin combinations do not establish MCI treatment benefit.
Read the illustrated explanation (Korean) →
Four separate assessment dimensions
| Effect direction and size | No directly eligible sole-biotin between-group cognitive effect was verified; improvement, null effect or harm is not directly established. |
|---|---|
| Evidence certainty | A direct-effect grade could not be validly assigned; related human evidence is separated from the target treatment effect. |
| Applicability | Adult MCI + oral sole-added biotin + cognition only; no extrapolation from diet, multimodal programs, other B vitamins, AD or dementia prevention. |
| Safety | Caution. Assay interference and unverified long-term direct MCI sole-biotin safety are kept separate from efficacy. |
Final grade=null and score=null. Raw C was not adopted because validation reported three required-axis errors for replication, independence and bias.
Useful facts when choosing a product
- This assessment does not certify the quality or authorization of a marketed product.
- The question concerns oral biotin as the sole additional active ingredient.
- The molecular form, active content, dose and excipients of an eligible product remain unverified.
- A research regimen is not a personal dosing recommendation.
Chamgap Semantic Classification Code
Permanent code issued
S.biotin-sole-added-active-mci.oral.adult-diagnosed-mci.defined-time-instrument-specific-cognition.oral-biotin-mci-actual-comparator-unverifiedSupplements and nutraceuticals > Biotin > Question: adults with diagnosed MCI; actual diagnostic criteria, subtype, deficiency and kidney function unverified > Question: validated cognitive-scale difference at a defined time; actual instrument, language and timing unverified > Unverified: actual control, common care and placebo excipients > Question: oral; actual route in a directly eligible study unverified
Original null/unscored state, three failed axes, unverified actual conditions and full bilingual reports preserved. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Biotin |
| Source or part used | Nutrient; actual manufacturing source and raw-material origin unverified |
| Formulation or processing | Question: oral sole-added active ingredient; actual molecular form, formulation and active content unverified |
| Route | Question: oral; actual route in a directly eligible study unverified |
| Dose | Unverified: no actual eligible dose or total intake |
| Duration | Unverified: no actual eligible treatment/follow-up duration |
| Population | Question: adults with diagnosed MCI; actual diagnostic criteria, subtype, deficiency and kidney function unverified |
| Effect or condition | Between-group cognitive-performance difference attributable to added biotin alone |
| Primary endpoint | Question: validated cognitive-scale difference at a defined time; actual instrument, language and timing unverified |
| Comparator | Unverified: actual control, common care and placebo excipients |
| Duplicate-detection key | R01|biotin|oral|COG|adults with diagnosed MCI |
What the research actually shows
Judgment
TASK-1039 / R01-079 · Existing site ID 3155 Question: In adults with mild cognitive impairment (MCI), does oral biotin supplementation as the sole added active ingredient improve cognitive function? Existing URL: https://chamgap.com/verdicts/cognition/oral-sole-biotin-diagnosed-mci-cognitive-function/ First published: 2026-09-17T07:59:07+00:00 (preserved) Evidence cutoff for this update: 20 September 2026
1. 30-second answer
The currently verified evidence does not establish that adding oral biotin alone improves cognition in adults with MCI. The human evidence located in the existing package and the targeted update consists of dietary-biotin observational studies, a multimodal case series in which biotin was only one possible component, and trials of other B vitamins or multinutrient regimens. None isolates the treatment effect of sole-added biotin. [S01–S07]
A 2026 systematic review/network meta-analysis of nutrient-supplement RCTs in healthy aging and MCI searched PubMed, Web of Science, Embase and CENTRAL through 21 December 2024 and reported 6,269 initial records → 2,910 after deduplication → 129 full texts → 41 RCTs across 21 treatment strategies, with no sole-biotin strategy listed. A 2022 vitamin/cognition systematic review explicitly searched biotin/vitamin H in PubMed, Web of Science and CENTRAL, reporting 22,875 initial records → 19,854 after deduplication → 212 full texts → 27 included articles; its included intervention groups did not list sole biotin. A 2026 MCI-specific supplement review and a July 2026 AD/MCI network meta-analysis likewise did not surface a sole-biotin trial in the accessible text. These are useful evidence maps, but they do not convert the treatment effect to zero. [S11–S13, S15]
Chamgap efficacy grade: unscored (null); score: null. This is not a one-line “insufficient data” conclusion. Human studies already exist in which biotin exposure and cognition/MCI were measured, so the rubric's ? condition—no human study measuring the claim's endpoint—cannot simply be equated with “no direct RCT found.” At the same time, no directly eligible sole-biotin MCI intervention was verified, so replication, funding independence and risk-of-bias axes cannot be filled truthfully. The calculator's raw C from the incomplete profile fails three required-axis validation checks and is therefore not adopted as the final grade.
This does not mean “biotin has no effect,” “biotin is safe,” or “the question was not researched.” It means that the direction and magnitude of this specific treatment claim cannot currently be determined from directly eligible evidence.
2. What exactly was judged
The page evaluates one independent claim with all of the following boundaries:
- Population: adults with MCI. Healthy older adults, the general population, Alzheimer disease, multiple sclerosis and post-cardiac-arrest hypoxic brain injury are different questions.
- Intervention: oral biotin as the sole added active ingredient. Dietary biotin, multivitamins/combinations, B6/B9/B12 and biotin analogues such as 2-iminobiotin are different interventions.
- Comparator: a comparison that can isolate the incremental effect of biotin alone.
- Endpoint: cognitive performance or a validated cognitive instrument at a defined time. Cognitive function itself is a treatment goal, so endpoint axis 1 is
P.
Planned question boundaries were kept separate from facts actually reported in studies. Because no directly eligible trial was verified, actual formulation, dose, duration, total dietary intake, deficiency status, MCI subtype, comparator excipients, cognitive instrument and assessment time remain unverified for the target intervention.
3. What evidence was checked
3.1 Directly eligible evidence
No study was verified that compared oral sole-added biotin with an appropriate control in adults with MCI and measured cognitive outcomes. Existing search assets were reused first. On 20 September 2026, targeted updates combined biotin/d-biotin with MCI, cognition, placebo/randomized and oral terms, plus ClinicalTrials.gov-focused searches. The current chat search interface did not expose official per-query total result counts, so no count was fabricated. Exact queries, dates, surfaced candidates and exclusion reasons are preserved in sources.json and verification_report.md.
3.2 Human evidence in the same nutrient/cognition area that is not the direct answer
| Evidence | What was actually observed | What it can tell us | What it cannot tell us |
|---|---|---|---|
| S02 Kim et al., 2018 | 242 adults aged ≥50; study-defined MCI n=36 and normal n=206. FFQ dietary intake plus cognitive testing. Dietary biotin was 14.60±1.62 µg/day in the MCI group vs 19.17±0.70 µg/day in the normal group, p=0.010. | Biotin intake and MCI/cognition have been measured together in humans; useful hypothesis-generating evidence. | No assigned supplement and no longitudinal treatment contrast; cannot estimate the causal effect or dose response of sole biotin supplementation in MCI. |
| S01 Kogan et al., 2026 | Retrospective multimodal MCI/AD case series, 51 enrolled and 22 retained ≥2.5 years. Diet, exercise, cognitive training, sleep, hormones and many supplements were combined. A typical list includes d-biotin 1–5 mg/day, but individual exposure denominators are not isolated. Mean MoCA among the 22 retained participants changed 21.7→22.5. | Cognition was followed in an MCI/AD program where biotin could be one component. | No control, multiple simultaneous interventions and substantial attrition; the 0.8-point within-group change is not a between-group biotin effect. |
| S03 Kong et al., 2025 | UK Biobank cohort of 122,959; dietary biotin and incident dementia. Q4 vs Q1 all-cause dementia HR 0.67 (0.56–0.81). | Observational association between dietary biotin and long-term dementia risk. | Not an MCI treatment trial, not cognitive-score improvement and not a sole-supplement effect. |
| S04 Zhang et al., 2026 | UK Biobank dietary biotin/dementia and brain imaging plus mouse mechanistic experiments; publicly funded. | Epidemiologic/mechanistic context. | Cannot be converted into a human sole-biotin MCI treatment effect. |
| S05–S07 | B6/B9/B12 or B-vitamin combination RCTs in MCI/AD. | Shows that cognitive trials in MCI exist for other B vitamins. | They are not biotin. Results for other B vitamins cannot be copied to biotin. |
| S11–S13, S15 | 2022/2026 systematic reviews/NMAs. S15 explicitly searched biotin/vitamin H; S11–S13 map supplement RCTs in healthy aging, MCI and/or AD. | Strengthens the evidence map showing no sole-biotin strategy among identified interventions. | Does not itself provide a biotin effect estimate and does not prove absolute absence of all later literature. |
3.3 Why the observational evidence was not treated as worthless
The scoring rubric explicitly allows observational studies to contribute when they are the decisive evidence and requires observational-study bias defects to be assessed rather than automatically calling such evidence worthless. S02 therefore matters: it documents that biotin intake and MCI/cognitive performance have been measured together in humans and provides a direction of association.
However, the current claim is a causal treatment claim about assigned sole-added biotin. A cross-sectional dietary comparison has a different intervention, comparator, time direction and estimand. Using it as the decisive treatment estimate would turn one research question into another. This is a boundary decision, not a claim that observational research has no value.
4. How the Chamgap scoring rules were applied
4.1 Endpoint and effect state
- Claim type:
B, clinical efficacy. - Endpoint:
P, because cognitive performance itself is the treatment target. - Effect magnitude: raw profile uses
EXto record that no eligible between-group mean difference, SD/SE, test statistic, CI or MCID can be calculated. TheEXcap of C is not an instruction to automatically assign C; the rest of the profile must also be valid. - Precision:
CX, because no directly eligible between-group CI was verified. This does not exclude meaningful benefit and does not establish equivalence.
4.2 Replication — why no R code was invented
Replication axis 2 classifies confirmatory trials and their agreement. R0 means genuine conflict among comparable trials, not “there are no trials.” No directly eligible confirmatory trial was verified here. Therefore R1, R2, R0, RX and RE cannot be assigned factually. Treating dietary S02, multimodal S01 and other-B-vitamin RCTs as repetitions of one another would combine different populations, interventions and estimands.
Final value: null (unsupported state in the current schema). This is neither conflict nor null efficacy.
4.3 Independence — explicit application of the I1 unknown-funding rule
Rubric precedent 29 says that when an existing decisive study cannot have its funding/conflict section checked, I2 must not be claimed; instead use I1 and explicitly say the funding source could not be confirmed. That rule prevents “not found” from being misreported as “independent.”
This case is different: there is no verified directly eligible decisive study whose funding is unknown. Assigning I1 would assert a mixed-funding state for a target study that has not been identified. A diagnostic run with only independence=I1 filled was performed; replication and bias remained invalid, so the rule does not solve the policy gap.
Funding reported for excluded indirect sources—such as S01 or the public support for S04—does not become the funding status of the target sole-biotin treatment evidence.
Final value: null (no directly eligible evidence to classify). The reason for not applying the I1 fallback is explicit.
4.4 Risk of bias — why B0/B1/B2 were not guessed
Axis 6 evaluates avoidable design, conduct and analysis defects in the decisive evidence supporting the claim. With no directly eligible decisive study, there is no target design on which to count B0/B1/B2 defects.
The limitations of indirect evidence are still described. S02 is a cross-sectional FFQ-based observational analysis; S01 is uncontrolled, multimodal and has substantial attrition. But transferring those defects to a nonexistent sole-biotin trial would confuse “why the available evidence is indirect” with “how many defects the decisive direct trial has.”
Final value: null (no directly eligible evidence to classify). No B code was imputed.
4.5 ? — why it was not assigned
The rubric's step 0 says ? applies when no human study has measured the endpoint of the claim, and it requires a reproducible search record containing database, exact query, date, result count and exclusion reasons. Two separate issues were considered.
- What is already known: S02 measured human cognition/MCI while measuring dietary biotin exposure. S01 followed cognition in MCI/AD in a multimodal program in which biotin could be present. Thus this is not a clean state of “biotin and this cognitive domain have never been measured in humans.” Those studies still do not answer the sole-supplement treatment question.
- Search-record completeness: Exact targeted queries were preserved, but this chat's search interface did not expose official PubMed/ClinicalTrials.gov total counts for each query. That limitation was not rewritten as a result count of zero. Conversely, no extra rule requiring proof of absolute absence across every database in the world was added.
Therefore the main reason ? is not adopted is not merely the missing count; it is the known existence of human biotin/cognition-MCI evidence. Missing official query totals are recorded separately as a work limitation.
4.6 Actual calculator run
The supplied rules/calculator.py (SHA-256 fdb27bbf68b61a276e46241f32af2b607b72300b1385589f08caeaebfb1e3744) was executed without modification.
Current raw profile: claim_type=B, endpoint=P, effect=EX, precision=CX, no_human_study=false, with replication=null, independence=null and bias=null.
derive_grade()raw output:Cvalidate_axes()errors: 3 — replication, independence and bias are not allowed values- CLI check: exit code 1
The raw C is therefore an intermediate output from incomplete input, not a valid final grade. Derivation and input validation are distinct stages. grading/ contains the input, stdout/stderr, exit code and diagnostic cases.
5. Why the grade remains unscored: three distinct layers
5.1 Evidence limitation
Within the searched scope and cutoff, no directly eligible effect estimate was verified for oral sole-added biotin in adults with MCI. Actual formulation, dose, duration, baseline biotin status, total dietary intake, MCI diagnostic criteria/subtype, comparator, instrument/language/time, arm denominators, effect, variance, CI, MCID and adverse events therefore cannot be extracted from a direct study.
Related evidence exists—dietary biotin and MCI/cognition (S02), dietary biotin and dementia (S03/S04), and a multimodal program (S01)—but it does not identify the incremental causal effect of sole biotin.
5.2 Assessment-system limitation
The rubric has ? for a state with no human endpoint study at all. Here, human biotin/cognition-MCI data exist, so that gate is not a straightforward fit. Yet the replication, independence and bias axes have no value meaning “no directly eligible decisive study to classify.” The rubric also has an observational-evidence rule, but S02's dietary cross-sectional estimand is not the target sole-supplement treatment estimand.
Consequently, leaving R/I/B as null triggers validation errors, whereas filling them with R/I/B codes would invent facts. This is the core reason for grading_status=not_scored_policy_gap.
5.3 Unfinished technical/search verification
- Official per-query total counts from PubMed and ClinicalTrials.gov were not obtained through the current chat search interface.
- The raw search screens of every bibliographic database were not independently operated in this same session; instead, existing search assets and accessible PubMed/PMC/publisher/ClinicalTrials records plus 2026 systematic-review search flows were reused and checked.
These limits are disclosed. They were not converted into “no study exists,” and they are not the sole cause of the unscored status. Known human biotin/cognition evidence already prevents a simple ? conclusion, while the direct-evidence and schema gaps remain.
6. What readers can and cannot conclude now
What can be said
- Human research has measured biotin intake together with MCI/cognitive performance. [S02]
- Large cohorts have reported observational associations between dietary biotin and dementia risk. [S03–S04]
- A multimodal MCI/AD program in which biotin could be one component reported cognitive follow-up. [S01]
- A 2022 review explicitly searching biotin/vitamin H and recent 2026 nutrition/MCI RCT evidence maps did not identify a sole-biotin strategy. [S11–S13, S15]
- “Biotin and cognition have never been studied in humans” is therefore different from “a directly eligible sole-biotin MCI treatment trial was not verified.”
What cannot be said
- That sole biotin improves cognition in MCI.
- That it has no effect, causes harm, or is equivalent to control.
- What dose, duration, MCI subtype or baseline nutritional state would matter, or whether any effect meets an MCID.
- That funding or bias characteristics of indirect sources can be used to fabricate the I/B axes of a nonexistent direct trial.
7. Safety
Safety is separate from efficacy. NIH ODS states that biotin can interfere with some biotin–streptavidin-based immunoassays, producing falsely high or falsely low results depending on the assay. FDA specifically warns that some susceptible troponin assays can yield falsely low results. This does not mean every laboratory platform is equally affected. [S08–S09]
The lack of an established upper intake level is not proof of safety for all high-dose or long-term use. Arm-specific adverse events, discontinuations and long-term exposure for a directly eligible MCI sole-biotin trial were not verified. Research doses are not personal dosing or medication-change instructions.
Safety label: Caution.
8. What evidence would change this assessment
Reassessment should preserve site ID 3155 and the existing URL if any of the following becomes available:
- An RCT or controlled study in adults with MCI comparing oral sole-added biotin with placebo/appropriate control and prespecifying a cognitive outcome.
- Verified details for formulation, dose, duration, MCI criteria/subtype, baseline nutritional status, total intake, cognitive instrument/time, arm-level effect/variance/CI, registration, funding/conflicts and adverse events.
- A directly relevant observational or quasi-experimental study that can be evaluated under the rubric's observational-design rules without changing the claim's intervention/estimand.
- An official rubric/calculator update that can represent related human evidence exists, but no directly eligible decisive study is available without inventing axis facts.
- A correction, retraction or extraction error affecting a material source.
9. Final judgment
Conclusion: With the evidence currently verified, oral sole-added biotin has not been shown to improve cognitive function in adults with MCI. Related human evidence exists, but it does not isolate the direct treatment effect.
Efficacy grade/score: null / null
grading_status: not_scored_policy_gap
result_status: completed_with_uncertainty
publication_status: ready_with_uncertainty
Safety: Caution
Document quality: A — meaning the requested source tracing, rule application, calculator execution, bilingual manuscript and uncertainty disclosures are complete, not that new direct evidence exists or that an independent external review has occurred.
10. Key sources
- S01. Kogan M, et al. The Integrative Personalized Functional Medicine Approach to Reverse Cognitive Decline: Academic Experience of the First 51 Patients Case Series. 2026. DOI 10.1177/27536130261452680. PMID 42221535.
- S02. Kim HL, et al. Association of Nutrient Intakes with Cognitive Function in Koreans Aged 50 years and Older. Clin Nutr Res. 2018;7(3):199-212. DOI 10.7762/cnr.2018.7.3.199. PMID 30079318.
- S03. Kong Y, et al. Association Between Dietary Biotin Intake and Dementia Risk, Including Alzheimer's Disease: A Prospective Study of 122 959 UK Biobank Participants. 2025. DOI 10.1002/mnfr.70252. PMID 40914826.
- S04. Zhang J, et al. Region-specific brain structural modulation and amyloid-β pathology associated with dietary biotin: insights into dementia neuropathology. eBioMedicine. 2026;125:106155. DOI 10.1016/j.ebiom.2026.106155. PMID 41679193.
- S11. Liu X, et al. Nutritional supplements and cognition in healthy aging and mild cognitive impairment patients: a systematic review and network meta-analysis. J Prev Alzheimers Dis. 2026;13(5):100518. DOI 10.1016/j.tjpad.2026.100518. PMID 41764841.
- S12. Wang X, et al. Effects of dietary supplements on cognitive outcomes and physiological biomarkers in mild cognitive impairment: a systematic review and network meta-analysis. Front Nutr. 2026;13:1775177. DOI 10.3389/fnut.2026.1775177.
- S13. Li Y, et al. The impact of supplements on cognitive function for Alzheimer's disease or mild cognitive impairment: a systematic review and network meta-analysis. Nutr Neurosci. 2026. DOI 10.1080/1028415X.2026.2703619. PMID 42494057.
- S15. Gil Martínez V, et al. Vitamin Supplementation and Dementia: A Systematic Review. Nutrients. 2022;14(5):1033. DOI 10.3390/nu14051033. PMID 35268010.
- S08. NIH Office of Dietary Supplements. Biotin: Fact Sheet for Health Professionals.
- S09. U.S. FDA. Biotin Interference with Troponin Lab Tests — Assays Subject to Biotin Interference.
Detailed URLs, access levels, exact search queries, source locations, exclusion reasons, and reused-versus-new verification status are recorded in sources.json and verification_report.md.
Why this is classified as Unscored
Known human biotin/cognition evidence means the ? no-human-endpoint-study condition is not met, yet no directly eligible decisive study exists to factually code replication, independence or bias. The I1 unknown-funding fallback presumes an evaluable study and is not used here. Raw C failed three validation checks and is not adopted.
Counterpoint. Actual dose, formulation, diagnostic criteria, cognitive instrument, between-group effect and CI remain unverified for a directly eligible trial. Per-query total result counts were not exposed, so absolute zero human studies is not claimed.
Rejudgment record. calculator_profile_invalid_with_three_unknown_required_axes — rules/scoring.md + rules/calculator.py + rules/verified_delivery_prompt.md
| Endpoint | P | Symptom or function itself is the target - including patient reports and performance tests |
| Effect size | EX | The clinical size of the effect could not be judged |
| Precision | CX | No pooled confidence interval could be confirmed |
Review performed and remaining limitations
Official per-query PubMed/ClinicalTrials.gov total counts were not obtainable through the current interface; this was not rewritten as zero or no research.
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Kogan et al., 2026 | Retrospective uncontrolled multimodal case series | 51 enrolled; 22 retained for at least 2.5 years; 29 discontinued in year one. MCI/AD-specific and actual biotin-exposure denominators were not reported. | No financial support reported; author ownership/advisory interests in an app and clinic were disclosed. | MoCA in retained participants; other cognitive tests, imaging and blood markers are separate. | Mean 21.7 to 22.5 is an uncontrolled within-group change, not an isolated between-group biotin effect. | Excluded from direct efficacy: multiple interventions, mixed diagnoses and no comparator. Used only as related human evidence and a boundary warning. |
| Kim et al., 2018 | Observational dietary intake-cognition association study | 242 total: 36 classified MCI and 206 normal; MCI classification used an average delayed verbal/visual score at or below the 16th percentile. | Funding unverified; the first-page no-conflict statement is not a funding-source confirmation. | CNS Vital Signs domains and EEG; not a biotin supplementation treatment effect. | Age-adjusted dietary biotin 14.60±1.62 vs 19.17±0.70 µg/day, p=0.010; a dietary association, not a causal treatment effect. | Excluded: FFQ dietary exposure, not an assigned oral sole-biotin supplementation comparison. |
| Kong et al., 2025 | Prospective UK Biobank dietary cohort | 122,959 participants; 1,256 incident dementia cases; median follow-up 11.25 years. | Funding unverified in the accessed abstract. | Incident dementia hazard by dietary intake, not a cognitive-scale difference in diagnosed MCI. | Top versus bottom quartile HR 0.67, 95% CI 0.56–0.81, for all-cause dementia is an observational association. | Excluded: dietary exposure and prevention events. Not a treatment effect with residual confounding or reverse causation ruled out. |
| Zhang et al., 2026 | UK Biobank dietary/brain-structure observations plus separate animal experiments | No question-matched arm denominator in the accessed material; the original cohort total is not substituted. | The abstract identifies National Natural Science Foundation of China support 82273619. | Dementia events/brain structure and separate mouse behavior/amyloid endpoints. | Human dietary associations and animal findings are not combined into an isolated biotin MCI cognitive effect. | Excluded: intervention, population and endpoint mismatch. Possible overlap with S03 is not independent treatment replication. |
| de Jager et al., VITACOG, 2012 | Randomized double-blind placebo-controlled MCI trial of folate/B12/B6 | 133 versus 133 participants aged at least 70; two years. | Funding unverified in this abstract-only review. | Cognitive outcomes are secondary; MMSE, CLOX, HVLT and fluency remain separate. | Favorable findings for some outcomes or higher-homocysteine subgroups are not biotin results. | Excluded: folate/B12/B6, not biotin. Other publications from the same VITACOG cohort are not new replications. |
| Kwok et al., 2020 | Randomized MCI trial of methylcobalamin/folic acid versus placebo | 279 participants aged at least 65; 24 months. | Funding unverified in the indexed abstract. | Primary CDR sum of boxes; secondary global CDR, memory/executive Z scores and depression. | No significant 24-month group difference was reported; intermediate within-group changes are not sustained between-group benefit. | Excluded: a non-biotin combination. Its nonsignificant result is not evidence that biotin is ineffective. |
| Aisen et al., 2008 | Randomized Alzheimer-disease trial of folate/B6/B12 versus placebo | 409 participants: 240 active and 169 placebo; 18 months. | NIA/NIH public support and Roche vitamin donations were confirmed; not funding for direct biotin evidence. | Primary ADAS-cog, 0–70 points with higher scores worse; baseline MMSE 14–26. | Lack of benefit on the primary rate comparison belongs to a different disease and intervention. | Excluded: AD rather than MCI and no biotin. Failures in other indications are not repeated refutations of this claim. |
| NIH ODS biotin professional fact sheet | Official nutrient and safety document | No efficacy-trial sample or arm denominator applies. | An agency document is not independent funding for a clinical efficacy trial. | Nutrient status, assay interference and limitations of high-dose safety evidence. | No established upper limit does not confirm all high-dose or long-term use is safe; susceptible assays can be biased in either direction. | Reused safety and nutrient context, not an MCI efficacy trial. |
| FDA biotin/troponin interference notice | Official regulatory safety information | No cognitive-efficacy denominator applies. | Regulatory information is a separate evidence layer. | Falsely low results in susceptible troponin assays. | This does not imply the same effect on every platform or an event in every user. | Supports a caution label, separate from cognitive efficacy. |
| Liu et al., 2026 systematic review/NMA | Evidence map of nutrient-supplement RCTs in healthy aging/MCI | 41 RCTs; 21 treatment strategies | Not used to classify independence of direct biotin efficacy evidence. | Cognitive function | No sole-biotin strategy appears in the listed interventions. | Indirect evidence map: supports non-identification of a direct trial, not proof of absolute zero studies. |
| Wang et al., 2026 MCI NMA | MCI dietary-supplement systematic review/NMA | Review-level; no direct biotin denominator | Not used to classify independence of direct biotin efficacy evidence. | Cognition/physiological biomarkers | No biotin match in accessible full text. | Indirect evidence map; pooled effects of other supplements not transferred to biotin. |
| Li et al., 2026 AD/MCI NMA | AD/MCI supplement systematic review/NMA | 29 trials, n=2,000 | Not used to classify independence of direct biotin efficacy evidence. | MMSE/ADAS-Cog and related outcomes | No biotin in accessible abstract/index. | Indirect evidence map; mixed AD/MCI and search cutoff July 2024. |
| NCT02836340 2-iminobiotin | Single-group 2-iminobiotin safety/PK after cardiac arrest | 21 participants | Not used to classify independence of direct biotin efficacy evidence. | Safety/PK and 30-day functional/cognitive follow-up | Biotin analogue, intravenous, post-cardiac-arrest population. | Excluded: wrong compound, route, population and control structure. |
| Gil Martínez et al., 2022 systematic review | Systematic review of vitamin supplementation and cognition/MCI/dementia | 22,875 records → 19,854 after deduplication → 212 full texts → 27 included articles | Not used to classify funding independence of a direct trial | Cognition/MCI/dementia; search explicitly included biotin/vitamin H | No sole-biotin intervention was listed among included intervention groups; B vitamins, D and E were included | Evidence-map support only; not a direct biotin estimate or proof of absolute absence. |
Receipt — 15 References
Evidence access cutoff: 2026-09-20. Each citation states its actual access level (full-text transcription, abstract, index, or other) and remaining limitations. Bibliographic checking does not certify the study results or treatment efficacy.
Technical integration by: Codex · Evidence date: 2026-09-20 · Corrections: 2
Revision history
2026-09-20: Updated the research manuscript and unscored rationale. The verdict ID, URLs, first publication date and null grade/score are unchanged. The no_human_study flag changed from null to false. Detailed changes are preserved in the full research report.
Cite this verdict
[Chamgap] Judgment — Oral sole-added biotin and cognition in adults with mild cognitive impairment — Evidence Grade Unscored. 15 cited sources checked. Source: https://chamgap.com/en/verdicts/cognition/oral-sole-biotin-diagnosed-mci-cognitive-function/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.